stockrow
Friday 6 November 2026
Export ADAPY’s income statement to Excel — free account
Adaptimmune Therapeutics PLC
ADAPY Healthcare Biotechnology
Adaptimmune Therapeutics PLC’s revenue for fiscal 2025 (year ended December 2025) was $5.9 million, down 96.7% from fiscal 2024.
- Revenue
- −89.3%
- EPS
- −140.7%
- Free cash flow
- −174.7%
Quarter to June 2025, against a year earlier
0.02
0.00
0.00%
Follow ADAPY
Alert me
| Dec '25 | Jun '25 | Mar '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 0.97 | 0.29 | 0.77 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (1.82) | (0.77) | (3.98) | |
P/B ratio |
— | 0.00 | 0.00 | 10.45 | |
Price to Tangible BV |
— | 0.00 | 0.00 | 30.18 | |
EV/Sales |
— | 0.97 | 0.10 | 0.20 | |
EV/EBITDA |
— | 0.00 | 1.57 | 4.44 | |
EV/Operating CF |
— | (0.33) | (0.16) | (0.48) | |
EV/FCF |
— | (0.33) | (0.16) | (0.46) | |
Quick Ratio |
— | 0.69 | 1.25 | 2.56 | |
Current Ratio |
— | 1.52 | 2.02 | 2.88 | |
Net Debt/EBITDA |
— | 0.01 | 0.79 | 19.15 | |
Debt/Assets |
0.00% | 19.65% | 16.08% | 20.39% | |
Debt/Equity |
— | (0.36) | (0.68) | 4.24 | |
Asset Turnover |
0.00 | 0.29 | 0.86 | 0.67 | |
Operating CF/Net income |
— | 1.15 | 1.40 | 0.45 | |
Capex/Depreciation |
— | (0.03) | (0.49) | (0.05) | |
Interest Coverage |
— | (31.48) | (24.31) | (38.02) | |
Research and Development Expense of Revenue |
— | 168.01% | 396.12% | 51.96% | |
Selling, General and Administrative Expense of Revenue |
— | 135.15% | 319.59% | 204.75% | |
Intangible Assets out of Total Assets |
0.00 | 0.03 | 0.02 | 0.03 | |
Share Based Compensation of Revenue |
— | 9.66% | 9.18% | 53.01% | |
Graham Net Nets |
— | (1.95) | (1.80) | (0.34) | |
Graham Number |
— | 1.98 | 0.94 | 0.00 | |
Earnings Yield |
— | (270.83%) | (135.00%) | (50.00%) | |
Free Cash Flow Yield |
— | (304.01%) | (215.64%) | (55.13%) | |
Revenue per Share |
— | 0.05 | 0.03 | 0.01 | |
Operating CF per Share |
— | (0.13) | (0.26) | (0.14) | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | (0.13) | (0.26) | (0.14) | |
Cash per Share |
— | 0.10 | 0.23 | 0.60 | |
Shareholders Equity per Share |
— | (0.27) | (0.15) | 0.05 | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
— | (0.27) | (0.15) | 0.05 | |
Free Cash Flow |
— | (34.85) | (67.79) | (34.56) | |
Working Capital |
— | 26.60 | 51.93 | 122.19 | |
Capital Expenditures |
— | (0.07) | (1.20) | (0.36) | |
Net Current Asset Value |
— | (123.48) | (92.50) | (46.34) | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.01 | 0.17 | 0.11 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 5.82 | 6.39 | 7.60 | |
Average Payables |
— | 8.47 | 6.14 | 24.56 | |
Average Assets |
158.72 | 226.17 | 208.04 | 264.52 | |
Average Common Equity |
— | 12.66 | (6.53) | 26.27 |
Columns are period end dates · fundamentals updated 26 Oct 2026